RACHEL EASTERS: Open Payments
NPI 1447640628 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,296 in 250 payments from 50 companies in 2025. Trend: 2023 $3,610 · 2024 $3,614 · 2025 $5,296
Food & beverage: $5,161Education: $166
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 22 | $551 |
| Novartis Pharmaceuticals Corporation | 24 | $494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $332 |
| PFIZER INC. | 15 | $324 |
| Celgene Corporation | 17 | $320 |
| Incyte Corporation | 10 | $273 |
| AstraZeneca Pharmaceuticals LP | 11 | $225 |
| GlaxoSmithKline, LLC. | 12 | $199 |
| SERVIER PHARMACEUTICALS LLC | 9 | $171 |
| Eisai Inc. | 8 | $141 |
Products named: REBLOZYL, RYBREVANT, FRUZAQLA, IMFINZI, LUTATHERA, Lenvima, KISQALI, TALVEY.
Industry payments across AL — which companies pay providers there.
